Progenics Pharmaceuticals Inc. (PGNX) Receives New Coverage from Analysts at Cantor Fitzgerald
The brokerage issued an overweight rating and a $15.00 price objective on the biotechnology company's stock. Several other research analysts also recently issued reports on the stock.
from Biotech News
0 Comments